



Immune Design
Investor Relations Department
Immune Design Corp. Attn:
Accounts Payab
601 Gateway Blvd. Suite 250
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: IMDZ

Last Trade:	5.20
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	4.50 - 13.05
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 23, 2017
[Immune Design Announces Proposed Public Offering of Common Stock](#)
- Oct 19, 2017
[Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin's Lymphoma](#)
- Oct 16, 2017
[Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients](#)
- Sep 25, 2017
[Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting](#)
- Sep 8, 2017
[New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 7, 2017
[Annual Report \(10-K\)](#)
- Apr 26, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017
[Quarterly Report \(10-Q\)](#)
- May 4, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016
[Quarterly Report \(10-Q\)](#)